Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Authors:
Open Access
- 1 April 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 101 (7) , 452-474
Abstract
In the clinical management of early-stage cutaneous melanoma, it is critical to determine which patients are cured by surgery alone and which should be treated with adjuvant therapy. To assist in this decision, many groups have made an effort to use molecular information. However, although there are hundreds of studies that have sought to assess the potential prognostic value of molecular markers in predicting the course of cutaneous melanoma, at this time, no molecular method to improve risk stratification is part of recommended clinical practice. To help understand this disconnect, we conducted a systematic review and meta-analysis of the published literature that reported immunohistochemistry-based protein biomarkers of melanoma outcome. Three parallel search strategies were applied to the PubMed database through January 15, 2008, to identify cohort studies that reported associations between immunohistochemical expression and survival outcomes in melanoma that conformed to the REMARK criteria. Of the 102 cohort studies, we identified only 37 manuscripts, collectively describing 87 assays on 62 distinct proteins, which met all inclusion criteria. Promising markers that emerged included melanoma cell adhesion molecule (MCAM)/MUC18 (all-cause mortality [ACM] hazard ratio [HR] = 16.34; 95% confidence interval [CI] = 3.80 to 70.28), matrix metalloproteinase-2 (melanoma-specific mortality [MSM] HR = 2.6; 95% CI = 1.32 to 5.07), Ki-67 (combined ACM HR = 2.66; 95% CI = 1.41 to 5.01), proliferating cell nuclear antigen (ACM HR = 2.27; 95% CI = 1.56 to 3.31), and p16/INK4A (ACM HR = 0.29; 95% CI = 0.10 to 0.83, MSM HR = 0.4; 95% CI = 0.24 to 0.67). We further noted incomplete adherence to the REMARK guidelines: 14 of 27 cohort studies that failed to adequately report their methods and nine studies that failed to either perform multivariable analyses or report their risk estimates were published since 2005.Keywords
This publication has 220 references indexed in Scilit:
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastasesClinical & Experimental Metastasis, 2007
- DNA damage signalling guards against activated oncogenes and tumour progressionOncogene, 2007
- Chemokines in tumor angiogenesis and metastasisCancer and Metastasis Reviews, 2007
- Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanomaBritish Journal of Cancer, 2007
- Nuclear ING2 expression is reduced in human cutaneous melanomasBritish Journal of Cancer, 2006
- FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patientsBritish Journal of Cancer, 2006
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- The Hallmarks of CancerCell, 2000
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986